It's not an easy day for holders of shares of medical companies involved in the production of COVID-19 vaccines. During the ongoing Tuesday session on Wall Street, companies such as Pfizer (PFE.US), Moderna (MRNA.US), BioNTech (BNTX.US) and Novavax (NVAX.US) are mostly diving by more than 5%. Novavax is losing the most, as the company's shares are currently down more than 10%. Pfizer today recorded its biggest daily drop since June 2020, sinking more than 5%.
The reasons for such a strong sell-off are not entirely clear. A calming down during today's session and a return to moderate gains on global exchanges may be partly behind the declines. However, the FDA reported today that Covid pills from Pfizer and Merck will be approved later this week. The virus appears to be accelerating, especially when it comes to the United States, where Omicron has become the dominant variant, overtaking the Delta variety. The White House has said it will send 1,000 military medics to help hospitals distribute free tests for Covid, which is expected to go free to more than 500 million people from January 2022.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appHowever, it seems most likely that some profit-taking may be taking place on the shares of the largest companies.
Pfizer (PFE.US), D1 interval. Currently, shares of the medical giant are falling from historical highs and were trading today near the 23.6 Fibo retracement. The company has been moving in a strong uptrend for over two months, with a strong support structure at the level of USD 55 per share (the local peak, which was bounced up, and a close convergence of the 23.6% and 38.2% retracements). Source: xStation 5
Moderna (MRNA.US) shares, D1 interval. Moderna's shares are moving in a dynamic downtrend, which over the last month began to take the form of an incomplete downtrend triangle. Breakout below the support at the level of USD 235 per share may encourage the supply side to accelerate declines up to the area of support at USD 193 per share. On the other hand, if the green support zone can be defended, the next resistance will be the breakout above the EMA 200 (yellow line). Source: xStation 5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
